This is a working overview of SR9009, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-10 and is reviewed periodically as new material appears.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
=== Major players === In terms of companies engaging directly in logistics, the sector in SA is highly competitive, with no dominant players. Among companies operating in the market are SA-based Transnet, UAE-based DP World (including its SA subsidiary Imperial Logistics), Switzerland-based Kuehne+Nagel, German-based DHL Group, and Denmark-based DSV (including German subsidiary DB Schenker).
=== Land mine usage === Since 1990, over 11,000 people have been killed or wounded by landmines in Colombia. According to the Presidential Program for Mine Action, between 1982 and the end of 2012, 2,038 people were killed by landmines. Since 2000, casualties from landmines in Colombia have ranged from 1,300 a year to around 550. In the past, the Colombian government laid landmines around 34 military bases to protect key infrastructure, but it renounced their use in 1997. Landmines are primarily used by rebel groups to protect their home bases and illegal drug crops, which fund the conflict. FARC and ELN have deployed antipersonnel mines throughout an estimated area of up to 100 square kilometers. In March 2015, FARC stated that it would begin humanitarian demining in selected parts of Colombia.
== Catabolism and clearance == The half-life of Lp(a) in circulation is approximately three to four days. The mechanism and sites of Lp(a) catabolism are largely unknown. The LDL receptor has been reported as a receptor for Lp(a) clearance, but is not a major pathway of Lp(a) metabolism under normal or hypercholesterolemic conditions. The kidney has been identified as playing a role in Lp(a) clearance from plasma.
== History == The application of mass spectrometry to study proteins became popularized in the 1980s after the development of MALDI and ESI. These ionization techniques have played a significant role in the characterization of proteins. (MALDI) Matrix-assisted laser desorption ionization was coined in the late 1980s by Franz Hillenkamp and Michael Karas. Hillenkamp, Karas and their fellow researchers were able to ionize the amino acid alanine by mixing it with the amino acid tryptophan and irradiated with a pulse 266 nm laser. Though important, the breakthrough did not come until 1987. In 1987, Koichi Tanaka used the "ultra fine metal plus liquid matrix method" and ionized biomolecules the size of 34,472 Da protein carboxypeptidase-A. In 1968, Malcolm Dole reported the first use of electrospray ionization with mass spectrometry. Around the same time MALDI became popularized, John Bennett Fenn was cited for the development of electrospray ionization. Koichi Tanaka received the 2002 Nobel Prize in Chemistry alongside John Fenn, and Kurt Wüthrich "for the development of methods for identification and structure analyses of biological macromolecules." These ionization methods have greatly facilitated the study of proteins by mass spectrometry. Consequently, protein mass spectrometry now plays a leading role in protein characterization.
Sources: en.wikipedia.org
A compartment kiln is filled with a static batch of timber through which air is circulated. In these types of kiln, the timber remains stationary. The drying conditions are successively varied according to the type of timber being dried. This drying method is well suited to the needs of timber companies, which have to dry timbers of varied species and thickness, including refractory hardwoods that are more liable than other species to check and split. The main elements of chamber drying are:
=== Final Cuban offensive === Although the SADF and UNITA counteroffensive had been checked, FAPLA remained heavily strained and more dependent than before on its Cuban allies and Soviet materiel. This gave dos Santos an incentive to ease the military dilemma with negotiations and he reopened the possibility of reaching a new ceasefire and disengagement agreement with South Africa. As early as January 1987, Chester Crocker had responded to positive signals from Luanda, especially when President Denis Sassou Nguesso of the People's Republic of the Congo offered to mediate peace talks between the rival states. Yet preliminary discussions in Brazzaville throughout late 1987 and early 1988 remained stymied by the Angolan government's refusal to compromise on the timetable for a proposed Cuban withdrawal. The Cuban government had not been consulted on the Brazzaville talks in advance and resented what it perceived as a discourtesy on the part of dos Santos. This factor had the effect of persuading Castro to make an authoritative bid to join the Angolan-US peace talks. He was determined that Cuba no longer be excluded from negotiations concerning its own military, and the results of any future settlement on the withdrawal process leave Cuba's image untarnished.
Vaccine production is fundamentally different from other kinds of manufacturing – including regular pharmaceutical manufacturing – in that vaccines are intended to be administered to millions of people of whom the vast majority are perfectly healthy. This fact drives an extraordinarily rigorous production process with strict compliance requirements that go far beyond what is required of other products. Depending upon the antigen, it can cost anywhere from US$50 to $500 million to build a vaccine production facility, which requires highly specialized equipment, clean rooms, and containment rooms. There is a global scarcity of personnel with the right combination of skills, expertise, knowledge, competence and personality to staff vaccine production lines. With the notable exceptions of Brazil, China, and India, many developing countries' educational systems are unable to provide enough qualified candidates, and vaccine makers based in such countries must hire expatriate personnel to keep production going. Vaccine production has several stages. First, the antigen itself is generated. Viruses are grown either on primary cells such as chicken eggs (e.g., for influenza) or on continuous cell lines such as cultured human cells (e.g., for hepatitis A). Bacteria are grown in bioreactors (e.g., Haemophilus influenzae type b). Likewise, a recombinant protein derived from the viruses or bacteria can be generated in yeast, bacteria, or cell cultures. After the antigen is generated, it is isolated from the cells used to generate it.
==== Hong Kong ==== The scandal led to an erosion of trust in locally produced infant formula and from then on, many Shenzhen residents and parallel traders travelled across the border to purchase powdered milk from Hong Kong shops. Lower confidence in mainland Chinese production, combined with the relaxation of visa requirements for mainland residents, had resulted in shortages of infant formula in Hong Kong for an extended time. Because of a great public outcry, the Import and Export (General) (Amendment) Regulation 2013 was passed in Hong Kong, prohibiting the unlicensed export of powdered formula, including milk and soya milk powder for infants and children under 36 months. According to the HK government, the regulation is not applicable to "powdered formula that is exported in the accompanied personal baggage of a person aged 16 or above leaving Hong Kong if the person did not leave Hong Kong in the last 24 hours and the formula does not exceed 1.8 kg [4 lb] in total net weight". Although the Hong Kong government imposed a strict 2-can limit on the export of infant formula in March 2013, spurred price differentials caused by sales tax on the mainland and lax customs, trafficking activity including for powdered milk has continued, exacerbating the Hong Kong-Mainland conflict. The catchment area for traffickers spread from Fan Ling and Sheung Shui southward to Yuen Long and Tuen Mun, causing localist camp such as Civic Passion and Hong Kong Indigenous to take to the streets in direct action in 2015.
===== Direct oral anticoagulants (DOACs) ===== DOACs are agents that inhibit the formation of thrombin which is the central effector of coagulation derived from factor Xa. They are categorised into direct thrombin inhibitors and direct factor Xa inhibitors. Direct thrombin inhibitors bind to the active sites of free or clot-bound thrombin to inhibit its effects. Dabigatran etexilate is a common example which has a rapid onset of action. Whereas direct factor Xa inhibitors including apixaban and rivaroxaban directly bind to clotting factor Xa to block its activity, thus inhibiting thrombin formation. DOACs are advantageous over warfarin because of a wider therapeutic window, which indicates safer and more effective use with minimal adverse effects. DOACs also have more stable and predictable anticoagulation effects. Therefore, routine coagulation monitoring is not required.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.